Prognostic impact of p16 and p53 gene expressions in stage 1a epithelial ovarian cancer
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
ObjectiveEpithelial ovarian cancer (EOC) is rarely detected at stage 1a. Most of the patients have a good prognosis and thereare limited factors that affect their survival. In the present study, we evaluated the p16 and p53 gene expressions ofstage 1a EOC patients. Prognostic effects of these gene expressions, as well as those of other factors on short termsurvival were analyzed. MethodsOur study included 29 patients. The specimens of the ovary with cancer were stained for p16 and p53. Geneexpressions and other prognostic factors were evaluated. ResultsThe median age of the patients was 51 years (27–84). The mean numbers of dissected pelvic and paraaortic lymphnodes were 27 and 12, respectively. The mean follow-up time was 33.7±18.9 months. During this period, recurrenceoccurred in two patients. One of the patients had grade 2 mucinous carcinoma and died of the disease at month12 after the recurrence occurred at month 7. The second patient had clear cell carcinoma and recurrence occurred atmonth 34. p16 and p53 gene expressions or other factors were not associated with overall survival (OS) or disease-free survival in the short term. The lower p16 positivity rate in the non-clear cell group was found to be statisticallysignificant (P=0.003). Both p53 and p16 positivity rates were higher in the high-grade carcinoma. ConclusionThe levels of none of the common prognostic factors, including those of p16 and p53 gene expression, wereassociated with the progression-free survival or OS of stage 1a in the short term. Appropriate surgical staging andnon-omission of subclinical metastases seem to be of central importance.
Abstract
ObjectiveEpithelial ovarian cancer (EOC) is rarely detected at stage 1a. Most of the patients have a good prognosis and thereare limited factors that affect their survival. In the present study, we evaluated the p16 and p53 gene expressions ofstage 1a EOC patients. Prognostic effects of these gene expressions, as well as those of other factors on short termsurvival were analyzed. MethodsOur study included 29 patients. The specimens of the ovary with cancer were stained for p16 and p53. Geneexpressions and other prognostic factors were evaluated. ResultsThe median age of the patients was 51 years (27–84). The mean numbers of dissected pelvic and paraaortic lymphnodes were 27 and 12, respectively. The mean follow-up time was 33.7±18.9 months. During this period, recurrenceoccurred in two patients. One of the patients had grade 2 mucinous carcinoma and died of the disease at month12 after the recurrence occurred at month 7. The second patient had clear cell carcinoma and recurrence occurred atmonth 34. p16 and p53 gene expressions or other factors were not associated with overall survival (OS) or disease-free survival in the short term. The lower p16 positivity rate in the non-clear cell group was found to be statisticallysignificant (P=0.003). Both p53 and p16 positivity rates were higher in the high-grade carcinoma. ConclusionThe levels of none of the common prognostic factors, including those of p16 and p53 gene expression, wereassociated with the progression-free survival or OS of stage 1a in the short term. Appropriate surgical staging andnon-omission of subclinical metastases seem to be of central importance.
참고문헌 (27)
- Ferlay J, "Cancer incidence and mortality worldwide : sources, methods and major patterns in GLOBOCAN 2012", Int J Cancer, 136, pp.E359~86 (2015)
- Chan JK, "Prognostic factors for high-risk early-stage epithelial ovarian cancer", Cancer, 112, pp.2202~2210 (2008)
- Ayhan A, "Textbook of gynaecolgical oncology", pp.429~431 (2011), Güneş Tıp Kitapevleri
- Vousden KH, "p53 in health and disease", Nat Rev Mol Cell Biol, 8, pp.275~283 (2007)
- Ayhan A, "Textbook of gynaecolgical oncology", pp.1056~1060 (2011), Güneş Tıp Kitapevleri
- McMenamin ME, "Extent of apoptosis in ovarian serous carcinoma : relation to mitotic and proliferative indices, p53 expression, and survival", Mol Pathol, 50, pp.242~246 (1997)
- Singer G, "Diverse tumorigenic pathways in ovarian serous carcinoma", Am J Pathol, 160, pp.1223~1228 (2002)
- Katsaros D, "Methylation of tumor suppressor gene p16 and prognosis of epithelial ovarian cancer", Gynecol Oncol, 94, pp.685~692 (2004)
- Rodriguez M, "National survey of ovarian carcinoma XII. Epithelial ovarian malignancies in women less than or equal to 25 years of age", Cancer, 73, pp.1245~1250 (1994)
- Schildkraut JM, "Prognostic factors in early-onset epithelial ovarian cancer : a population-based study", Obstet Gynecol, 95, pp.119~127 (2000)
- Zanetta G, "The accuracy of staging : an important prognostic determinator in stage I ovarian carcinoma. A multivariate analysis", Ann Oncol, 9, pp.1097~1101 (1998)
- Ayhan A, "Oncologic and reproductive outcome after fertilitysaving surgery in ovarian cancer", Eur J Gynaecol Oncol, 24, pp.223~232 (2003)
- Colombo N, "Controversial issues in the management of early epithelial ovarian cancer : conservative surgery and role of adjuvant therapy", Gynecol Oncol, 55, pp.S47~51 (1994)
- Mutch DG, "Danforth’s obstetrics and gynecology", pp.1023~1060 (2008), Lippincott Williams & Wilkins
- Le T, "The benefits of comprehensive surgical staging in the management of early-stage epithelial ovarian carcinoma", Gynecol Oncol, 85, pp.351~355 (2002)
- Chan J, "The treatment and outcomes of early-stage epithelial ovarian cancer : have we made any progress?", Br J Cancer, 98, pp.1191~1196 (2008)
- Seidman JD, "Pathology of ovarian carcinoma", Hematol Oncol Clin North Am, 17, pp.909~925 (2003)
- Ellenson LH, "Robbins and Cotran pathologic basis of disease", pp.1092~1104 (2005), Elsevier Saunders
- Kurman RJ, "Pathogenesis of ovarian cancer : lessons from morphology and molecular biology and their clinical implications", Int J Gynecol Pathol, 27, pp.151~160 (2008)
- Darcy KM, "Associations between p53 overexpression and multiple measures of clinical outcome in high-risk, early stage or suboptimally-resected, advanced stage epithelial ovarian cancers A Gynecologic Oncology Group study", Gynecol Oncol, 111, pp.487~495 (2008)
- Skírnisdóttir IA, "Prognostic impact of p53, p27, and C-MYC on clinicopathological features and outcome in early-stage(FIGO I-II)epithelial ovarian cancer", Int J Gynecol Cancer, 21, pp.236~244 (2011)
- Skírnisdóttir I, "Prognostic impact of concomitant p53 and PTEN on outcome in early stage(FIGO I-II)epithelial ovarian cancer", Int J Gynecol Cancer, 21, pp.1024~1031 (2011)
- de Graeff P, "Modest effect of p53, EGFR and HER-2", neu on prognosis in epithelial ovarian cancer : a metaanalysis, 2009, pp.101, 149~159
- García-Velasco A, "Prognostic value of hormonal receptors, p53, ki67 and HER2", neu expression in epithelial ovarian carcinoma, 2008, pp.10, 367~371
- Lee YK, "Prognostic value and clinicopathological significance of p53 and PTEN in epithelial ovarian cancers", Gynecol Oncol, 112, pp.475~480 (2009)
- Khouja MH, "The clinical importance of Ki-67, p16, p14, and p57 expression in patients with advanced ovarian carcinoma", Int J Gynecol Pathol, 26, pp.418~425 (2007)
- Surowiak P, "Decreased expression of p16 in ovarian cancers represents an unfavourable prognostic factor", Histol Histopathol, 23, pp.531~538 (2008)